ELDN

Eledon Pharmaceuticals, Inc. (ELDN) - 10-K Summary

Business Context and Reporting Period

Company: Eledon Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Eledon is a clinical-stage biotechnology company developing tegoprubart, an anti-CD40L antibody. The company focuses on preventing organ transplant rejection (kidney, xenotransplantation, islet cell) and treating Amyotrophic Lateral Sclerosis (ALS). The company has no approved products and generates no product revenue.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company recorded a non-cash gain of $33.4 million due to the change in fair value of warrant liabilities, which reduced the reported net loss.

Material Changes vs. Prior Period

• Increased R&D Spend: Research and development expenses increased by $14.3 million (28%) primarily due to higher external CRO costs for the Phase 1b and Phase 2 BESTOW kidney transplantation trials and increased manufacturing costs.
• Decreased G&A: General and administrative expenses decreased by $1.6 million, driven largely by a $2.6 million reduction in stock-based compensation expense.
• Financing Activity: The company raised approximately $53.6 million in net proceeds from a November 2025 underwritten offering. In 2024, the company raised significantly more capital ($133.5 million net) through multiple private placements and an underwritten offering.
• Warrant Liability Reduction: The fair value of warrant liabilities decreased from $44.9 million to $11.4 million, reflecting a decline in the company's stock price.

Guidance, Outlook, and Risks

Clinical Progress:

• Kidney Transplantation: Topline data from the Phase 2 BESTOW trial (announced Nov 2025) showed tegoprubart maintained strong renal function (eGFR ~69 mL/min) compared to tacrolimus (~66 mL/min). While the primary endpoint did not reach statistical significance, the company believes the results support approvability if replicated in Phase 3. The company plans to seek FDA guidance for a Phase 3 trial design in 2026.
• Islet Cell Transplantation: Preliminary data from an investigator-initiated trial showed all six subjects achieved insulin independence.
• ALS: The company states it is unable to continue clinical development for ALS without additional financing.

Liquidity and Capital Needs:

• The company estimates sufficient cash resources to fund operations for at least the next 12 months from the filing date (March 2026).
• Additional funding is explicitly required to continue the ALS program and to advance kidney transplantation into Phase 3.
• Future capital raises may result in significant dilution to existing shareholders.

Risks and Contingencies:

• Profitability: The company expects to continue incurring losses and may never achieve profitability.
• Internal Controls: The company previously identified a material weakness in internal controls related to equity instrument accounting. Management concluded this weakness was remediated as of December 31, 2025.
• Regulatory: Drug development is uncertain; failure to demonstrate safety/efficacy in future trials could halt the business.

Key Facts for Investor Verification

• Cash Runway: Verify the specific date by which the company expects to exhaust its $133.3 million cash balance, particularly given the stated need for additional funding for the ALS program.
• Phase 3 Design: Monitor the FDA feedback expected in 2026 regarding the Phase 3 kidney transplantation trial design, as this is the critical path to commercialization.
• Dilution Risk: Review the terms of outstanding warrants (51.8 million shares underlying) and pre-funded warrants, which represent significant potential dilution.
• ALS Program Status: Confirm whether the company secures specific financing for the ALS program, as current liquidity is insufficient to continue this development track.
• Internal Controls: Monitor future filings to ensure the remediated material weakness regarding equity accounting does not reoccur.